Future Fund LLC Buys 12,091 Shares of Halozyme Therapeutics, Inc. $HALO

Future Fund LLC boosted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 14.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 95,121 shares of the biopharmaceutical company’s stock after acquiring an additional 12,091 shares during the quarter. Halozyme Therapeutics accounts for 2.2% of Future Fund LLC’s holdings, making the stock its 3rd largest position. Future Fund LLC owned approximately 0.08% of Halozyme Therapeutics worth $6,148,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of HALO. Arrowstreet Capital Limited Partnership boosted its position in Halozyme Therapeutics by 29.5% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 3,290,665 shares of the biopharmaceutical company’s stock worth $241,337,000 after purchasing an additional 749,484 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Halozyme Therapeutics by 1.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,104,157 shares of the biopharmaceutical company’s stock valued at $141,613,000 after purchasing an additional 25,731 shares during the period. Norges Bank acquired a new position in shares of Halozyme Therapeutics in the 4th quarter valued at $128,201,000. William Blair Investment Management LLC purchased a new stake in Halozyme Therapeutics during the fourth quarter worth $124,031,000. Finally, Federated Hermes Inc. boosted its holdings in Halozyme Therapeutics by 8.5% during the fourth quarter. Federated Hermes Inc. now owns 1,574,621 shares of the biopharmaceutical company’s stock worth $105,972,000 after buying an additional 123,917 shares in the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock opened at $77.81 on Friday. The stock has a market capitalization of $9.23 billion, a P/E ratio of 27.99, a P/E/G ratio of 0.32 and a beta of 0.84. The company’s fifty day moving average price is $72.03 and its 200 day moving average price is $70.20. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76. Halozyme Therapeutics, Inc. has a 1 year low of $55.64 and a 1 year high of $82.26.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.06. The company had revenue of $376.71 million during the quarter, compared to analysts’ expectations of $358.60 million. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The firm’s revenue for the quarter was up 42.2% on a year-over-year basis. During the same period in the prior year, the business posted $1.11 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. As a group, equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Halozyme Therapeutics news, Director Mahesh Krishnan sold 7,304 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $75.00, for a total transaction of $547,800.00. Following the completion of the sale, the director directly owned 14,462 shares in the company, valued at approximately $1,084,650. The trade was a 33.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $71.75, for a total value of $1,435,000.00. Following the transaction, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at $55,088,215. The trade was a 2.54% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 74,102 shares of company stock worth $5,205,798 in the last 90 days. Insiders own 2.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on HALO. Morgan Stanley cut their price objective on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. UBS Group reissued a “buy” rating and set a $90.00 target price on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Weiss Ratings upgraded Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, May 12th. HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, June 16th. Finally, Benchmark reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Eight analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $81.60.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.